In retina surgery, obtaining prior authorization is an extra burden, and a delay in treatment for some of these patients could mean loss of vision, said Sabin Dang, MD, ophthalmologist with The Retina Institute.
In retina surgery, obtaining prior authorization is an extra burden, and a delay in treatment for some of these patients could mean loss of vision, said Sabin Dang, MD, ophthalmologist with The Retina Institute.
Transcript
Is there a common reason for prior authorization denial and are there best practices for preventing a denial?
What we have found in the field of ophthalmology and specifically retina surgery is we are incredibly successful at getting prior authorizations. So, when our field asks for a prior authorization, the data we collected in our study shows that we're successful in 99.5% of prior authorization requests. So, to say, is there a common reason for denials? There really isn't one. Bottom line is, when clinicians are asking to use the medication, it's done so appropriately.
When we dig into that 0.5% of denials, oftentimes those are very rare conditions that are potentially off label that are not very common. And those are the instances where we're seeing it. But the vast majority is definitely approved on the first go.
What impact are prior authorizations for anti–vascular endothelial growth factor (VEGF) medications having on patient treatment and outcomes?
With patients with retinal disease, oftentimes timing is very critical. These are often diseases that can be potentially blinding diagnoses, and timely treatment can give a patient better outcomes in the long run. We as clinicians do our best with a prior authorization landscape to obtain those authorizations and still provide timely treatment. But we do run into barriers.
For example, we could have an elderly patient who comes in with their family member and is diagnosed with a condition that requires treatment. We are unable to obtain prior authorization that day. So, we say, “Please come back. We're willing to see you tomorrow or the day after once we obtain prior authorization.” But the patient's family member may have already taken all the time off work they can that week, and they say, “Well, I'm sorry, we won't be able to come at least for another 1 to 2 weeks.” And if that's the best you can do, that's the best you can do. But you really are risking harm to that patient’s long-term vision in these situations.
So, it is a huge burden that we have now placed on patients and their family members by adding this one extra hurdle in the process.
What other potential issues could arise if care with anti-VEGF therapy is delayed due to prior authorizations?
If a patient has a delay in care, we do run the risk of permanent vision loss. That is the No. 1 concern we have as eye care providers is that a delay in treatment may lead to irreversible vision loss. Thankfully, we typically do have a few days, but that is not always the case. Sometimes we see patients with truly emergent pathology, where timing is critical. Where they require treatment within the next 24 hours in order to save their vision or even save their eye. So, it’s absolutely important that they receive timely treatment in order to get the best outcome.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More